

HOLD TP: Rs 175 | ¥ 4%

**FINOLEX INDUSTRIES** 

Plastic Products

28 June 2021

# **Higher PVC prices boost profitability**

- FNXP reported strong Q4FY21 revenue growth of 63% YoY as PVC prices surged 68% YoY, driving up realisations
- Operating margin beat estimates, expanding 20ppt YoY to 32.8% primarily due to a higher gross margin (+14ppt)
- We raise FY22/FY23 PAT ~18% and increase our TP to Rs 175 (vs. Rs 135).
   Realign from ADD to HOLD (as per our new rating scale) on full valuations

Strong revenue growth aided by higher PVC prices: FNXP reported revenue growth of 63% YoY as PVC prices surged 68% YoY and PVC pipe realisation increased 48%. PVC resin volumes grew 25% YoY whereas pipe volumes declined 4%. Management stated that Q4 was its best-ever quarter aided by record PVC resin realisations which offset the negative impact of higher prices on agriculture PVC pipe demand. For FY21, revenue grew 16% YoY with PVC resin/pipe volumes declining 1%/17% YoY whereas realisation increased 37%/24% YoY.

**Agri pipe demand softens:** Q1FY22 which is a busy season for agriculture pipes has been affected by both the higher PVC prices and the pandemic. The non-agri segment continues to do well (~37% of revenue in FY21) and management is hopeful of better volumes from agri pipes in H2FY22.

Operating margin swells 20ppt YoY: FNXP's standalone EBITDA margin increased 20ppt YoY to 32.8% aided by a higher gross margin (14ppt) from better PVC realisations, as well as lower other expenses (-500bps). EBITDA/PBT thus grew 296%/421% YoY. Similarly, for FY21, the company reported a 14ppt rise in operating margin to 28.6%, resulting in EBITDA/PBT growth of 121%/148% YoY.

**PVC prices have begun to correct:** The average PVC-EDC delta was at US\$ 877/mt (+53% YoY) in Q4, US\$ 711 (+27% YoY) in FY21 and currently stands at US\$ 715/mt. As per management, PVC prices have started to correct in Q1FY22 whereas EDC prices have remained firm, resulting in margin pressure. While PVC resin margins are difficult to forecast, those in the pipe segment are more predictable and should sustain at ~Rs 10/kg according to FNXP.

**Valuations full, HOLD:** We raise FY22/FY23 PAT estimates 18%/19% given the Q4 margin beat. FNXP has a strong balance sheet and its focus on non-agri pipes could aid further margin gains. While we like the company, we find current valuations full at 24.9x FY23E P/E. We realign to HOLD (from ADD) as per our new rating scale. Post estimate revision, we raise our Mar'22 TP to Rs 175 (from Rs 135), set at 24x FY23E P/E – a 30% premium to the five-year average vs. 20% earlier.

### **Arun Baid**

researchreport@bobcaps.in

## Key changes

Target	Rating
<b>A</b>	<b>4 &gt;</b>

Ticker/Price	FNXP IN/Rs 182	
Market cap	US\$ 1.5bn	
Free float	48%	
3M ADV	US\$ 2.0mn	
52wk high/low	Rs 198/Rs 27	
Promoter/FPI/DII	52%/3%/45%	


Source: NSE | Price as of 28 Jun 2021

### **Key financials**

Y/E 31 Mar	FY21P	FY22E	FY23E
Total revenue (Rs mn)	34,628	34,395	35,344
EBITDA (Rs mn)	9,893	5,962	6,281
Adj. net profit (Rs mn)	7,378	4,209	4,537
Adj. EPS (Rs)	11.9	6.8	7.3
Consensus EPS (Rs)	9.4	7.4	8.2
Adj. ROAE (%)	28.8	12.9	13.0
Adj. P/E (x)	15.3	26.9	24.9
EV/EBITDA (x)	11.4	18.5	16.9
Adj. EPS growth (%)	121.8	(43.0)	7.8

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

## Stock performance



Source: NSE





Fig 1 – Standalone quarterly performance

(Rs mn)	Q4FY21	Q4FY20	YoY (%)	Q3FY21	QoQ (%)	FY21	FY20	YoY (%)
Net sales	12,493	7,687	62.5	10,669	17.1	34,628	29,845	16.0
COGS	6,417	5,009	28.1	5,863	9.4	19,288	19,427	(0.7)
Employee expenses	593	408	45.6	368	61.4	1,668	1,456	14.6
Other expenses	1,382	1,234	12.0	971	42.3	3,780	4,489	(15.8)
EBITDA	4,101	1,035	296.1	3,467	18.3	9,893	4,474	121.1
EBITDA margin (%)	32.8	13.5	1,935bps	32.5	33bps	28.6	15.0	1,358bps
Depreciation & amortisation	197	189	4.3	199	(0.8)	777	738	5.3
EBIT	3,904	846	361.1	3,268	19.4	9,116	3,736	144.0
EBIT margin (%)	31.2	11.0	2,023bps	30.6	61bps	26.3	12.5	1,381bps
Other income	135	10	1,281.6	182	(25.4)	725	308	135.0
Finance costs	18	85	(78.3)	18	2.8	73	113	(35.5)
Profit before tax	4,021	771	421.2	3,432	17.2	9,768	3,932	148.4
Tax expenses	1,047	214	388.7	873	19.9	2,488	690	260.6
Reported Net profit	2,973	557	433.7	2,559	16.2	7,280	3,242	124.6

Source: Company, BOBCAPS Research

Fig 2 – Standalone segmental performance

(Rs mn)	Q4FY21	Q4FY20	YoY (%)	Q3FY21	QoQ (%)	FY21	FY20	YoY (%)
Revenue								
PVC	9,202	4,362	111.0	6,920	33.0	22,733	16,777	35.5
PVC pipes & fittings	9,017	6,322	42.6	7,258	24.2	26,353	25,540	3.2
Total	18,219	10,683	70.5	14,178	28.5	49,086	42,316	16.0
Inter-segment revenues	5,726	2,997	91.1	3,509	63.2	14,458	12,471	15.9
Net sales (inc. other op. inc.)	12,493	7,687	62.5	10,669	17.1	34,628	29,845	16.0
EBIT								
PVC	3,285	314	947.7	2,456	33.7	6,964	1,996	248.9
PVC pipes & fittings	695	625	11.1	914	(23.9)	2,512	2,022	24.2
Total	3,980	939	323.8	3,370	18.1	9,476	4,018	135.8
EBIT Margins (%)								
PVC	35.7	7.2	2,850bps	35.5	19bps	30.6	11.9	2,380bps
PVC pipes & fittings	7.7	9.9	(219bps)	12.6	(488bps)	9.5	7.9	(21bps)
Total	31.9	12.2	1964bps	31.6	27bps	27.4	13.5	1,839bps

Source: Company, BOBCAPS Research



Fig 3 - Consolidated quarterly performance

(Rs mn)	Q4FY21	Q4FY20	YoY (%)	Q3FY21	QoQ (%)	FY21	FY20	YoY (%)
Net sales	12,493	7,687	62.5	10,669	17.1	34,628	29,845	16.0
COGS	6,417	5,009	28.1	5,863	9.4	19,288	19,427	(0.7)
Employee expenses	593	408	45.6	368	61.4	1,668	1,456	14.6
Other expenses	1,382	1,234	12.0	971	42.3	3,780	4,489	(15.8)
EBITDA	4,101	1,035	296.1	3,467	18.3	9,893	4,474	121.1
EBITDA margin (%)	32.8	13.5	1,935bps	32.5	33bps	28.6	15.0	1,358bps
Depreciation & amortisation	197	189	4.3	199	(0.8)	777	738	5.3
EBIT	3,904	846	361.1	3,268	19.4	9,116	3,736	144.0
EBIT margin (%)	31.2	11.0	2,023bps	30.6	61bps	26.3	12.5	1,381bps
Other income	135	10	1,281.6	182	(25.4)	716	299	139.2
Finance costs	18	85	(78.3)	18	2.8	73	113	(35.5)
Profit before tax	4,021	771	421.2	3,432	17.2	9,759	3,923	148.8
Tax expenses	1,062	301	253.3	896	18.6	2,543	852	198.5
Share of profit from associates	30	116	(74.0)	58	(47.8)	162	256	(36.7)
Reported Net profit	2,988	587	409.4	2,594	15.2	7,378	3,327	121.8

Source: Company, BOBCAPS Research

Fig 4 – Volume & Realisation

Particulars	Q4FY21	Q4FY20	YoY (%)	Q3FY21	QoQ (%)	FY21	FY20	YoY (%)
Volume								
PVC (MT)	75,281	60,100	25.3	67,741	11.1	2,36,087	2,39,188	(1.3)
PVC pipes (MT)	60,232	62,464	(3.6)	55,299	8.9	2,12,060	2,54,958	(16.8)
Realisation								
PVC (Rs/t)	1,22,241	72,571	68.4	1,02,149	19.7	96,291	70,141	37.3
PVC pipes (Rs/t)	1,49,704	1,01,207	47.9	1,31,250	14.1	1,24,271	1,00,171	24.1
EBIT/tonne								
PVC (Rs/t)	43,631	5,216	736.4	36,262	20.3	29,498	8,344	253.5
PVC pipes (Rs/t)	11,537	10,012	15.2	16,519	(30.2)	11,845	7,932	49.3

Source: BOBCAPS Research, Company

Fig 5 – PVC-EDC delta


PVC/EDC Spread	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
Spread (US\$/mt)	523	490	583	589	574	547	654	765	877
YoY (%)	(33.4)	(28.8)	(9.0)	10.1	9.8	11.6	12.2	29.9	52.8

Source: Company, BOBCAPS Research




## STANDALONE QUARTERLY TRENDS

Fig 1 - PVC resin revenue growth



Source: Company, BOBCAPS Research

Fig 3 - PVC resin EBIT margin




Source: Company, BOBCAPS Research

Fig 5 - PVC pipes & fittings revenue growth




Source: Company, BOBCAPS Research

Fig 2 - PVC resin volume growth




Source: Company, BOBCAPS Research

Fig 4 – PVC pipes & fittings EBIT margin



Source: Company, BOBCAPS Research

Fig 6 - PVC pipes & fittings volume growth



Source: Company, BOBCAPS Research



# Earnings call highlights

- PVC prices reached historical highs in Q4FY21 which aided a strong performance for FNXP.
- PVC resin prices have declined from an average of US\$ 1,483/mt in Q4 to
  US\$ 1,380/mt currently but remain well above the historical mean of US\$ 900-950.
   The company expects prices to stay elevated in the range of US\$ 1,100-1,200 due
  to supply issues in near-term.
- During Q4, the average PVC-EDC delta stood at US\$ 877/mt (vs.US\$ 574/mt in Q4FY20). This delta has currently fallen to US\$ 715/mt.
- With PVC prices correcting from Q4 levels and the PVC-EDC delta falling, FNXP expects margins to come off historic highs.
- Management did not give out guidance for PVC resin margins as these are volatile, but believes they could stabilise at ~Rs 15,000/t when the pricing situation normalises. In PVC pipes, management has guided for sustainable margins of ~Rs 10,000/t.
- Agriculture demand was affected by the higher PVC resin prices in Q4 and further dampened by the second wave of the pandemic in Q1FY22. Management believes demand for agri pipes would return in H2FY22. On the non-agricultural side, there was no material impact on demand from higher PVC prices.
- During Q4, agri pipe volumes declined 14% YoY whereas the non-agri segment grew 22%. For FY21, agri pipe volumes declined 21% and non-agri fell 4.5% YoY.
- Agri pipes contributed 63% of turnover for the year. Management is targeting a higher 40% share from the non-agri segment going forward.
- CPVC volumes increased 67% YoY in Q4 and 4% YoY in FY21 to 9,635mt.
- In FY22, FNXP aims to match FY19 sales volume of ~263,000mt (+24% YoY) despite a tepid Q1.
- South and West India are the major markets for the company and account for ~75% of total revenue.
- Current pipe capacity is 370,000mtpa which includes 20,000t of CPVC capacity and is sufficient to meet demand for a couple of years.
- The capex plan for FY22 totals Rs 1bn but will be increased if demand in the pipe segment picks up.
- The company remains net cash-surplus.



# Valuation methodology

FNXP is one of the major PVC pipe players in India with 22,000 dealers, sub-dealers and retailers spread across the country. The company has a strong presence in the agricultural pipe market and plans to build a significant footprint in the plumbing market following its foray into CPVC pipes.

We raise FY22/FY23 PAT estimates by 18%/19% given above-expected margins in the PVC resin segment. Our Mar'22 TP stands revised to Rs 175 (from Rs 135), set at a higher 24x FY23E P/E multiple (vs. 22x earlier) – a 30% premium to the five-year average vs. 20% earlier. We believe FNXP merits a premium to historical multiples due to its strong balance sheet and near-term earnings upsides from higher PVC prices.

Though we like the company for its sound balance sheet and growing focus on the high-margin non-agri segment, current valuations look full at 24.9x FY23E P/E. We thus realign to HOLD (from ADD) as per our new rating scale.

Fig 7 - Revised estimates

(Rs mn)		Old		Change (%)		
(KS IIII)	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	34,395	35,344	32,058	34,488	7.3	2.5
EBIDTA	5,962	6,281	5,023	5,249	18.7	19.7
PAT	4,209	4,537	3,557	3,802	18.3	19.3

Source: BOBCAPS Research

Fig 8 - Key assumptions

Key assumptions	FY19	FY20	FY21P	FY22E	FY23E
PVC resin external sales (mt)	66,680	55,599	80,468	70,007	61,606
Growth (%)	(1)	(17)	45	(13)	(12)
PVC pipe volumes (mt)	2,62,858	2,54,958	2,12,060	2,39,628	2,68,383
Growth (%)	4	(3)	(17)	13	12
PVC pipe EBITDA (Rs/mt)	8,471	9,587	13,844	10,000	10,000
Growth (%)	28	13	44	(28)	0
PVC resin EBITDA (Rs/mt)	15,273	8,940	31,086	15,000	14,900
Growth (%)	9	(41)	248	(52)	(1)

Source: BOBCAPS Research

Fig 9 - Peer comparison

Commonic	Detina	Target Price	Revenue CAGR	EPS (F	Rs)	ROE (%	6)	Target P/E
Company	Rating	(Rs)	FY21-23E (%)	FY22E	FY23E	FY22E	FY23E	(x)
Kajaria Ceramics	REDUCE	950	19	24.0	29.6	19.9	23.3	32
Somany Ceramics	BUY	640	16	21.8	29.1	13.2	15.3	22
Greenply Industries	ADD	230	19	9.2	11.3	23.0	22.9	20
Century Plyboard	SELL	370	19	11.9	14.7	19.1	19.6	25
Greenpanel Industries	BUY	295	24	12.1	16.3	18.4	20.4	18
Cera Sanitaryware	HOLD	4,145	16	115.4	138.1	16.2	17.1	30
Astral Ltd	SELL	1,210	16	20.2	25.2	20.3	22.6	48
Finolex Industries	HOLD	175	1	6.8	7.3	12.9	13.0	24
Supreme Industries	SELL	1,805	8	52.8	60.1	20.2	20.8	30

Source: BOBCAPS Research

# **FINOLEX INDUSTRIES**



# **Key risks**

Key downside risks to our estimates are:

- volatility in PVC-EDC spreads,
- slowdown in agricultural/housing markets, and
- increased competition from unorganised players, leading to lower profitability



# **Financials**

Income Statement Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue	30,913	29,860	34,628	34,395	35,344
EBITDA	6,043	4,481	9,893	5,962	6,281
Depreciation	(701)	(738)	(777)	(894)	(954)
EBIT	5,342	3,743	9,116	5,068	5,327
Net interest inc./(exp.)	(123)	(119)	(73)	(82)	(59)
Other inc./(exp.)	404	299	716	481	547
Exceptional items	0	0	0	0	017
EBT	5,624	3,923	9,759	5,467	5,816
Income taxes	(1,812)	(852)	(2,543)	(1,418)	(1,529)
Extraordinary items	(279)	0	0	0	(1,020)
Min. int./Inc. from assoc.	140	256	162	160	250
Reported net profit	3,672	3,327	7,378	4,209	4,537
Adjustments	184	0	0	0	4,001
Adjusted net profit	3,857	3,327	7,378	4,209	4,537
rajuotou not pront	0,001	0,021	1,010	4,200	4,001
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21P	FY22E	FY23E
Accounts payables	2,838	2,334	3,952	2,709	2,755
Other current liabilities	1.387	1,723	3,085	2.356	2,227
Provisions	230	297	420	471	484
Debt funds	906	2,827	2,039	1,239	439
Other liabilities	2.205	1,873	2,053	1,943	1,833
Equity capital	1,241	1,241	1,241	1,241	1,241
Reserves & surplus	24,521	18,619	30,149	32,458	34,953
Shareholders' fund	25,762	19,860	31,390	33,699	36,194
Total liab. and equities	33,327	28,913	42,939	42,255	43,737
Cash and cash eq.	291	932	3,363	3,193	3,269
Accounts receivables	743	732	1,480	918	940
Inventories	6,205	8,578	9,188	8,155	8,209
Other current assets	1,035	710	779	918	940
Investments	13,619	6,607	16,792	16,992	17,692
Net fixed assets	9,489	10,153	10,013	10,642	11,216
CWIP	902	73	82	50	50
Intangible assets	20	16	11	11	11
Deferred tax assets, net	0	0	0	0	
Other assets	1,023	1,113	1,233	1,376	1,410
Total assets	33,327	28,913	42,939	42,255	43,737
	00,02.		,	,	.0,. 0.
Cash Flows					
Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21P	FY22E	FY23E
Cash flow from operations	3,535	1,057	9,209	3,665	4,558
Capital expenditures	(1,366)	(603)	(647)	(1,469)	(1,500)
Change in investments	0	0	0	0	(1,000)
Other investing cash flows	(1,605)	942	(5,859)	(200)	(700)
Cash flow from investing	(2,971)	340	(6,507)	(1,669)	(2,200)
Equities issued/Others	0	0	0	0	(2,200)
Debt raised/repaid	(101)	1,921	(788)	(800)	(800)
Interest expenses	(123)	(119)	(73)	(82)	(59)
Dividends paid	(1,532)	(2,873)	(42)	(1,889)	(2,042)
Other financing cash flows	1,416	315	632	604	619
Cash flow from financing	(340)	(756)	(271)	(2,167)	(2,282)
Chg in cash & cash eq.	223	641	2,431	(170)	76
-	291			-	3,269
Closing cash & cash eq.	231	932	3,363	3,193	3,209

Per Share Y/E 31 Mar (Rs)	FY19A	FY20A	FY21P	FY22E	FY23E
Reported EPS	5.9	5.4	11.9	6.8	7.3
Adjusted EPS	6.2	5.4	11.9	6.8	7.3
Dividend per share	2.0	2.0	4.0	2.5	2.7
Book value per share	41.5	32.0	50.6	54.3	58.3
Dook value per strate	41.5	32.0	30.0	J4.J	30.0
Valuations Ratios					
Y/E 31 Mar (x)	FY19A	FY20A	FY21P	FY22E	FY23E
EV/Sales	3.7	3.8	3.3	3.2	3.0
EV/EBITDA	18.8	25.1	11.4	18.5	16.9
Adjusted P/E	29.3	34.0	15.3	26.9	24.9
P/BV	4.4	5.7	3.6	3.4	3.1
DuPont Analysis					
Y/E 31 Mar (%)	FY19A	FY20A	FY21P	FY22E	FY23E
Tax burden (Net profit/PBT)	68.6	84.8	75.6	77.0	78.0
Interest burden (PBT/EBIT)	105.3	104.8	107.1	107.9	109.2
EBIT margin (EBIT/Revenue)	17.3	12.5	26.3	14.7	15.1
Asset turnover (Rev./Avg TA)	90.4	95.9	96.4	80.6	81.9
Leverage (Avg TA/Avg Equity)	1.3	1.4	1.4	1.3	1.2
Adjusted ROAE	14.4	14.6	28.8	12.9	13.0
Ratio Analysis					
Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
YoY growth (%)					
Revenue	12.9	(3.4)	16.0	(0.7)	2.8
EBITDA	24.9	(25.9)	120.8	(39.7)	5.3
Adjusted EPS	28.9	(13.8)	121.8	(43.1)	8.1
Profitability & Return ratios (%)					
EBITDA margin	19.5	15.0	28.6	17.6	18.5
EBIT margin	17.3	12.5	26.3	15.0	15.8
Adjusted profit margin	12.5	11.1	21.3	12.5	13.2
Adjusted ROAE	14.4	14.6	28.8	12.9	13.0
ROCE	19.2	15.2	32.5	14.7	15.1
Working capital days (days)					
Receivables	7	9	12	13	10
Inventory	117	139	168	149	140
Payables	39	37	46	43	34
Ratios (x)					
Gross asset turnover	1.4	1.3	1.5	1.4	1.3

Source: Company, BOBCAPS Research | Note: TA = Total Assets

1.5

43.5

0.0

1.5

31.4

0.1

1.6

0.0

125.4

2.0

61.3

(0.1)

2.3

92.1

(0.1)

Current ratio

Net interest coverage ratio

Adjusted debt/equity



# **Disclaimer**

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

## Ratings and Target Price (3-year history): FINOLEX INDUSTRIES (FNXP IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

## Rating distribution

As of 31 May 2021, out of 95 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 47 have BUY ratings, 19 have ADD\* ratings, 6 are rated REDUCE\* and 23 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (\*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

# Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

## General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years.

BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation

### **FINOLEX INDUSTRIES**



or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.